These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11209964)

  • 21. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model.
    Allen GP; Kaatz GW; Rybak MJ
    Int J Antimicrob Agents; 2004 Aug; 24(2):150-60. PubMed ID: 15288314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae.
    Zhanel GG; Walters M; Laing N; Hoban DJ
    J Antimicrob Chemother; 2001 Apr; 47(4):435-40. PubMed ID: 11266416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutant prevention concentrations of pradofloxacin for susceptible and mutant strains of Escherichia coli with reduced fluoroquinolone susceptibility.
    Marcusson LL; Komp Lindgren P; Olofsson SK; Hughes D; Cars O
    Int J Antimicrob Agents; 2014 Oct; 44(4):354-7. PubMed ID: 25129317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of fluoroquinolones in tuberculosis today.
    Berning SE
    Drugs; 2001; 61(1):9-18. PubMed ID: 11217874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis.
    Dong Y; Zhao X; Kreiswirth BN; Drlica K
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2581-4. PubMed ID: 10952625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci.
    Kaneko A; Sasaki J; Shimadzu M; Kanayama A; Saika T; Kobayashi I
    J Antimicrob Chemother; 2000 Jun; 45(6):771-5. PubMed ID: 10837428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maximizing efficacy and reducing the emergence of resistance.
    Wise R
    J Antimicrob Chemother; 2003 May; 51 Suppl 1():37-42. PubMed ID: 12702702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy.
    Aubert G; Pozzetto B; Dorche G
    J Antimicrob Chemother; 1992 Mar; 29(3):307-12. PubMed ID: 1317371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using In Vitro Dynamic Models To Evaluate Fluoroquinolone Activity against Emergence of Resistant Salmonella enterica Serovar Typhimurium.
    Lee SJ; Awji EG; Park NH; Park SC
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative minimal inhibitory and mutant prevention drug concentrations of four fluoroquinolones against ocular isolates of Haemophilus influenzae.
    Hedlin P; Blondeau JM
    Eye Contact Lens; 2007 May; 33(3):161-4. PubMed ID: 17502752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gatifloxacin: a review of its use in the management of bacterial infections.
    Perry CM; Ormrod D; Hurst M; Onrust SV
    Drugs; 2002; 62(1):169-207. PubMed ID: 11790160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutant prevention concentration and phenotypic and molecular basis of fluoroquinolone resistance in clinical isolates and in vitro-selected mutants of Escherichia coli from dogs.
    Gebru E; Damte D; Choi MJ; Lee SJ; Kim YH; Park SC
    Vet Microbiol; 2012 Jan; 154(3-4):384-94. PubMed ID: 21893387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmacodynamic and pharmacokinetic evaluation of respiratory fluoroquinolones. Guideline to selection of the most appropriate fluoroquinolone].
    Parra-Ruiz J; Hernández-Quero J
    Rev Esp Quimioter; 2012 Dec; 25(4):245-51. PubMed ID: 23303254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters.
    Pickerill KE; Paladino JA; Schentag JJ
    Pharmacotherapy; 2000 Apr; 20(4):417-28. PubMed ID: 10772373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Mutant Prevention Concentration: is it significant in the clinical practice?].
    Pea F
    Infez Med; 2008 Apr; 16 Suppl2():12-21. PubMed ID: 18843220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative mutant prevention concentrations of pradofloxacin and other veterinary fluoroquinolones indicate differing potentials in preventing selection of resistance.
    Wetzstein HG
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4166-73. PubMed ID: 16189094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Fluoroquinolones--a current review].
    Christ W; Kemmler H
    Med Monatsschr Pharm; 2001 Jul; 24(7):215-25. PubMed ID: 11486553
    [No Abstract]   [Full Text] [Related]  

  • 39. Bacterial resistance to fluoroquinolones: lessons to be learned.
    Ball P
    Infection; 1994; 22 Suppl 2():S140-7. PubMed ID: 7927833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones.
    Wispelwey B
    Clin Infect Dis; 2005 Jul; 41 Suppl 2():S127-35. PubMed ID: 15942879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.